Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• The Bcr-Abl tyrosine kinase is a key driver of chronic myeloid leukemia (CML).
• Continuous inhibition of Bcr-Abl by imatinib was considered essential for maximal therapeutic benefit in CML.
• The clinical efficacy of dasatinib with once-daily dosing, despite its short half-life, prompted re-evaluation of inhibition duration.

Purpose of the Study:

• To investigate whether transient Bcr-Abl inhibition can achieve therapeutic efficacy in CML.
• To determine if in vitro pharmacokinetic modeling can predict clinical outcomes for kinase inhibitors.
• To challenge the paradigm that continuous target inhibition is necessary for optimal kinase inhibitor efficacy.

Main Methods:

• Treatment of CML progenitor cells and cell lines with dasatinib or nilotinib at clinically relevant concentrations.
• Short-term (4-hour) and continuous (72-hour) drug exposure followed by washout.
• Assessment of apoptosis induction and reduction in clonogenic cells.
• Modeling of in vivo pharmacokinetics using in vitro assays.

Main Results:

• Both transient (4-hour) and continuous (72-hour) dasatinib treatment induced apoptosis and reduced clonogenic cells in CML progenitor cells.
• Acute dasatinib exposure irreversibly committed Bcr-Abl+ CML cell lines to apoptosis.
• Transient inhibition with nilotinib also led to cell death.
• In vitro assays modeling pharmacokinetics successfully predicted clinical efficacy.

Conclusions:

• Continuous Bcr-Abl inhibition is not required for optimal efficacy of kinase inhibitors in CML.
• Transient, potent inhibition can be sufficient to induce apoptosis and reduce CML cell viability.
• In vitro pharmacokinetic modeling is a valuable tool for predicting clinical effectiveness of kinase inhibitors.